United Therapeutics CFO sells 10,000 shares in plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $146.03 per share and sold 10,000 shares in multiple open-market trades at prices between $533.25 and $549.17, all pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 shares of common stock and held 8,750 stock options.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($3.94M approx. pre-tax spread)
Exercise and Sale
16 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.40M)
Approx. gross sale proceeds
$5.40M
Approx. exercise cost
$1.46M
Approx. pre-tax spread
$3.94M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $146.03 | $1.46M |
| Sale | Common Stock | 400 | $533.587 | $213K |
| Sale | Common Stock | 160 | $534.475 | $86K |
| Sale | Common Stock | 210 | $536.2721 | $113K |
| Sale | Common Stock | 600 | $537.2397 | $322K |
| Sale | Common Stock | 1,440 | $538.3079 | $775K |
| Sale | Common Stock | 2,035 | $539.4173 | $1.10M |
| Sale | Common Stock | 2,978 | $540.2175 | $1.61M |
| Sale | Common Stock | 865 | $541.0582 | $468K |
| Sale | Common Stock | 192 | $541.8846 | $104K |
| Sale | Common Stock | 40 | $543.5268 | $22K |
| Sale | Common Stock | 40 | $545.19 | $22K |
| Sale | Common Stock | 265 | $547.3683 | $145K |
| Sale | Common Stock | 115 | $547.8052 | $63K |
| Sale | Common Stock | 660 | $548.9021 | $362K |
Holdings After Transaction:
Stock Option — 8,750 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (14)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $541.82 to $542.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $543.37 to $543.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $546.69 to $547.545. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $547.69 to $548.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $548.69 to $549.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $533.25 to $533.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $534.39 to $534.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $535.73 to $536.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $536.76 to $537.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $537.78 to $538.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $538.78 to $539.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $539.78 to $540.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $540.78 to $541.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Options exercised: 10,000 shares
Exercise price: $146.03 per share
+3 more
6 metrics
Shares sold
10,000 shares
Open-market sales of common stock on June 18, 2026
Options exercised
10,000 shares
Stock option exercise converting into common stock
Exercise price
$146.03 per share
Strike price for 10,000 stock options exercised
Sale price range
$533.25–$549.17 per share
Ranges from multiple trade executions noted in footnotes
Shares owned after
18,876 shares
Direct common stock holdings following transactions
Remaining stock options
8,750 options
Stock options outstanding after the reported exercise
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, open market or private transaction, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open market or private transaction financial
"Sale in open market or private transaction"
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?
He reported exercising options for 10,000 United Therapeutics shares and selling 10,000 shares in open-market trades. These transactions were part of a pre-arranged Rule 10b5-1 trading plan and left his direct holdings at 18,876 shares of common stock.
At what price did the United Therapeutics (UTHR) CFO exercise his stock options?
He exercised stock options covering 10,000 United Therapeutics shares at an exercise price of $146.03 per share. This converted derivative holdings into common stock before the related open-market sales reported in the same Form 4 filing.
Were the United Therapeutics (UTHR) CFO’s trades made under a Rule 10b5-1 plan?
Yes. A footnote states the option exercise and subsequent share sales were made pursuant to a Rule 10b5-1 trading plan that James Edgemond entered into on October 31, 2025, indicating the transactions were pre-arranged rather than opportunistic.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates